Loading organizations...
Promentis Pharmaceuticals is a technology company.
Promentis Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric disorders. The company's primary asset, SXC-2023, targets specific conditions such as trichotillomania (hair-pulling disorder). Promentis leverages a foundational understanding of glutamate system dysfunction within the central nervous system to identify and advance novel therapeutic candidates with the potential to address significant unmet medical needs.
The company was co-founded in 2007 by David A. Baker, Ph.D. Dr. Baker, then a professor at Marquette University’s Department of Biomedical Sciences, initiated Promentis based on his research into neurological mechanisms. His insight centered on translating fundamental scientific discoveries regarding glutamate’s role in brain function into tangible pharmacological solutions for complex psychiatric and neurological conditions.
Promentis aims to serve patients suffering from neuropsychiatric conditions, starting with those afflicted by trichotillomania, for whom effective treatment options are scarce. The company’s long-term vision is to deliver targeted, effective therapies that significantly improve the lives of individuals managing various neuropsychiatric disorders, ultimately bringing new hope to this patient population.
Promentis Pharmaceuticals has raised $29.0M across 2 funding rounds.
Promentis Pharmaceuticals has raised $29.0M in total across 2 funding rounds.
Promentis Pharmaceuticals has raised $29.0M in total across 2 funding rounds.
Promentis Pharmaceuticals's investors include OrbiMed, Stacey Seltzer, Thomas Beck, Patrick Schwarz-Schutte, Golden Angels Investors, Black Horse Investments.
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing innovative oral therapies for neuropsychiatric and neurodevelopmental disorders, targeting unmet needs like trichotillomania—a prevalent condition with no approved treatments—through modulation of glutamate signaling in brain regions linked to urge control and executive function.[1][2][3][4] The company serves patients with obsessive-compulsive, addictive, and other CNS disorders, addressing gaps in current treatments via novel compounds engaging System xc-, a key CNS target.[3][4] With $64.9M in total funding across 11 rounds and Phase 2 initiation for lead candidate SXC-2023 in 2019, Promentis shows steady clinical momentum despite being pre-approval.[4][6]
Promentis Pharmaceuticals emerged as a biopharma venture focused on CNS therapeutics, with its first institutional investment from F-Prime Capital in 2016, based in Milwaukee, Wisconsin.[1] While specific founders are not detailed in available records, the company quickly prioritized trichotillomania as its lead indication, building on scientific insights into glutamate dysregulation implicated in obsessive-compulsive and addictive behaviors.[3][4] A pivotal early moment was the 2019 announcement of Phase 2 dosing for SXC-2023, targeting a novel glutamatergic mechanism, which advanced its pipeline amid growing recognition of System xc- as a psychiatric target.[4][6]
Promentis rides the wave of precision neuroscience, targeting glutamatergic pathways amid rising demand for non-dopamine-based therapies for psychiatric disorders, where traditional treatments fall short for conditions like trichotillomania and addictions.[3][4] Timing aligns with advances in understanding System xc- signaling, bolstered by market forces like increasing CNS disorder prevalence and biopharma's shift toward oral small molecules over biologics for brain penetration.[1][6] By pioneering therapies for underserved indications, Promentis influences the ecosystem, potentially validating new targets and attracting follow-on investment in neuropsychiatric innovation.[2][4]
Promentis is poised for Phase 2/3 readouts on SXC-2023, with recent 2024 trial activity signaling momentum toward potential first approval in trichotillomania or adjacent indications like cocaine disorders.[4][6] Trends in glutamate modulation and AI-driven CNS drug design could accelerate expansion, though success hinges on clinical efficacy data and partnership funding in a competitive biopharma landscape. Its influence may grow by filling therapy voids, redefining neuropsychiatric treatment possibilities as it began—through targeted innovation.[3]
Promentis Pharmaceuticals has raised $29.0M across 2 funding rounds. Most recently, it raised $26.0M Series C in March 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2017 | $26.0M Series C | OrbiMed, Stacey Seltzer, Thomas Beck | Patrick Schwarz-Schutte, Golden Angels Investors |
| Jan 22, 2014 | $3.0M Series B | Black Horse Investments | Golden Angels Investors |